GlassScriptPhysician profile
Lindsay Cala
NPI 1437598083
$4,996.77
in general payments reported to CMS, 2019-2025
37 companies · $398 in 2025
The $398 reported for 2025 was more than what 80% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $778 · 2021: $1,221 · 2022: $641 · 2023: $938 · 2024: $637 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,926 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,926.19 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $864.70 | 2021-2025 | Ubrelvy, Vraylar, Linzess |
| Astrazeneca Pharmaceuticals LP | $397.11 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $374.16 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $362.03 | 2019-2025 | |
| Amgen INC. | $308.43 | 2019-2024 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $241.44 | 2020-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $211.96 | 2020-2021 | |
| Novo Nordisk INC | $201.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lundbeck LLC | $197.75 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $153.04 | 2023-2025 | Veozah, Myrbetriq |
| Avanir Pharmaceuticals, INC. | $137.49 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.51 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $132.08 | 2022-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $130.09 | 2022-2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $113.46 | 2019-2021 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Cala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.